Vietnam Antacids Market Overview, 2031

Key Insights

• Traditional antacids, which rely exclusively on basic mineral salts (such as calcium carbonate or magnesium hydroxide) to neutralize gastric acid, are increasingly yielding shelf space to advanced dual-action and multi-mechanism products. The most significant formulation advancement in recent years is the global adoption of sodium alginate raft-forming barriers paired with fast-acting antacid salts. Rather than simply buffering stomach pH, these formulations react with gastric fluids to create a physical gel raft that floats on top of stomach contents. This physically blocks acid reflux into the esophagus while neutralizing excess gastric acid.
• Health authorities worldwide (including the U.S. FDA, European Medicines Agency, and national health boards) have implemented initiatives to reduce chronic, long-term over-prescription of Proton Pump Inhibitors (PPIs) like omeprazole due to safety risks such as bone density loss, kidney complications, and gut microbiota disruption. Physicians are actively encouraging step-down protocols for mild-to-moderate heartburn patients. This regulatory push has redirected millions of occasional reflux sufferers back toward non-prescription, fast-acting OTC antacids, alginates, and H2 blockers for on-demand symptom management.
• Consumer buying patterns in the antacid space are shifting from traditional heavy glass bottles of liquid suspension to ultra-portable, consumer-friendly formats. To appeal to health-conscious and elderly demographics, manufacturers are introducing low-sodium, sugar-free, and natural/herbal hybrid antacids combining mineral buffering salts with mucosal-soothing botanicals (such as aloe vera, liquorice, and chamomile) or targeted probiotics for dual acid relief and long-term stomach mucosal protection.

Market Outlook

• While traditional retail pharmacies dominate distribution, digital pharmacy platforms and online subscription models are emerging as the fastest-growing retail sales vector, driven by quick-commerce home delivery and automated reordering for chronic sufferers. Future product development is expected to feature next-generation dual-action therapies that integrate fast-acting buffering agents with gastric microbiome restoratives, moving the market from temporary symptom relief toward holistic gastrointestinal care.
• The global regulatory and clinical direction is guided by organizations such as the World Gastroenterology Organisation (WGO), International Foundation for Gastrointestinal Disorders (IFFGD), and national bodies like the FDA and EMA; commercial supply is led by major pharmaceutical and consumer healthcare leaders including Reckitt Benckiser Group (Gaviscon), Bayer AG (Rennie, Alka-Seltzer, Talcid), Haleon / GSK (Eno, Tums), Sanofi (Maalox, Phosphalugel), Procter & Gamble (Pepto-Bismol), Takeda Pharmaceutical, and Akums Drugs and Pharmaceuticals.

Market Dynamics

Driver: Rising prevalence of acid reflux and digestive disorders
The primary driver for the antacids market is the increasing prevalence of heartburn, acid reflux, GERD and other digestive disorders, combined with greater consumer willingness to manage mild symptoms through OTC medicines. Changing dietary habits, processed-food consumption, stress and sedentary lifestyles are contributing to digestive discomfort, while greater awareness of digestive health is encouraging consumers to seek treatment earlier.
Challenge: Competition from PPIs, H2 blockers and natural alternatives
A major challenge is substitution from other gastrointestinal treatments. Consumers have access to proton-pump inhibitors (PPIs), H2 antagonists and other acid-reducing medicines that can provide longer-lasting acid suppression than conventional acid-neutralizing antacids. At the same time, consumers increasingly consider probiotics, herbal remedies, dietary changes and other natural approaches for digestive discomfort.
Trend: Shift toward convenient, differentiated and digital OTC formats
The market is increasingly moving toward consumer-friendly formulations and omnichannel distribution. Chewable tablets, flavored liquids, sugar-free products and other convenient formats are being developed to improve taste, portability and ease of use. Recent industry reporting highlights innovation in sugar-free and chewable formulations, as well as pediatric- and geriatric-friendly products. Distribution is also evolving. Retail pharmacies remain a major channel, but online pharmacies and e-commerce are gaining importance, allowing consumers to compare products and purchase OTC digestive remedies conveniently.

Segment Analysis

Antacids Market By Drug Class
• Acid neutralizers remain the core rapid-relief category because they directly neutralize acid already present in the stomach rather than preventing its production. Calcium carbonate, magnesium hydroxide, aluminium hydroxide and sodium bicarbonate are established active ingredients. Different salts also create different formulation characteristics, including speed of neutralization, duration and gastrointestinal tolerability. Modern antacids are primarily positioned for mild, intermittent symptoms rather than long-term disease control.
• Proton Pump Inhibitors (PPIs) represent a longer-acting acid-control approach and are particularly relevant when heartburn occurs repeatedly. Unlike conventional antacids, PPIs reduce acid production at the gastric proton pump. The FDA describes OTC PPIs as products intended for frequent heartburn and notes that their full effect can take 1-4 days, demonstrating why they are not substitutes for immediate antacid relief.
• H2 antagonists occupy an intermediate therapeutic position because they reduce gastric acid production while generally acting faster than PPIs. The FDA notes that OTC H2 blockers typically begin working within 1–3 hours and can provide acid suppression for several hours. This makes the class attractive for consumers seeking longer symptom control without using a PPI regimen.
• Pro-motility agents form a specialized segment because their principal purpose is to influence gastrointestinal movement and gastric emptying rather than directly neutralize gastric acid. They can become relevant when reflux-like symptoms coexist with delayed gastric emptying, bloating or post-meal fullness. Their clinical positioning is therefore substantially different from traditional consumer antacids.
• Combination formulations are increasingly important because upper-GI symptoms frequently overlap. Antacid-plus-simethicone products can address acidity and gas simultaneously, while antacid-alginate combinations can combine acid neutralization with a physical reflux-barrier mechanism. Combination products therefore compete on broader symptom coverage and convenience rather than simply on acid-neutralizing capacity. Antacid formulations containing simethicone are recognized in pharmacological references as a way of addressing associated gas symptoms.



Antacids Market By Dosage Form • Tablets and chewables remain one of the most practical dosage forms because they provide portable, pre-measured administration without requiring water or measuring devices. Chewable products are especially suitable for immediate use after meals or when symptoms arise outside the home. The format also allows manufacturers to differentiate through flavour, texture, tablet size and combination ingredients.
• Liquid suspensions offer flexibility for consumers who have difficulty swallowing tablets and allow manufacturers to incorporate relatively high concentrations of mineral-based antacid ingredients. Suspension uniformity is an important formulation consideration because the active ingredients must remain adequately dispersed. Accurate dosing, shaking instructions, viscosity and flavour can strongly influence consumer acceptance.
• Powders provide a portable, non-tablet alternative that can be packaged in individual sachets or other single-dose formats. They can be designed for rapid dissolution or dispersion before administration. Their main competitive limitation is the additional preparation step compared with ready-to-use liquids and chewables, making packaging convenience particularly important.
• Gels and syrups provide smooth administration and can support distinctive sensory positioning. Gel formulations containing alginates are particularly interesting because they can provide a physical barrier against reflux in addition to the effects of an antacid. Syrups can appeal to consumers who prefer liquid medicines and allow manufacturers to differentiate through flavour and viscosity.
• Gummies and other formats represent a newer consumer-oriented direction within gastrointestinal self-care. Their appeal comes from portability, palatability and familiar administration. However, conventional antacid ingredients can require substantial active-ingredient loading, making it difficult to maintain both therapeutic delivery and confectionery-like taste and texture. Effervescent and rapidly dispersible products therefore remain useful alternatives for convenience-focused innovation.

Antacids Market By Indication • Gastroesophageal Reflux Disease (GERD) is one of the most important indications supporting the broader antacid and acid-control category. Antacids are particularly suited to mild, intermittent GERD symptoms, while recurrent or more severe disease generally requires stronger acid-suppressive treatment. NIDDK notes that antacids can relieve mild GERD symptoms, whereas PPIs are more effective for GERD and can heal the oesophageal lining in most patients.
• Heartburn is the most directly consumer-recognizable indication and remains central to antacid self-care. It occurs when acidic stomach contents move back toward the oesophagus and produces the characteristic burning sensation behind the breastbone or in the upper abdomen. Because consumers can often recognize the symptom without a formal diagnosis, heartburn strongly supports OTC purchasing and rapid-relief formulations.
• Peptic ulcer represents a more clinically managed indication. Although antacids can reduce acid-related discomfort, they have largely been displaced by acid-suppressive therapy for ulcer treatment. PPIs have become central to ulcer-healing strategies and are also used in treatment regimens addressing H. pylori. Consequently, antacids are better positioned as supplementary or short-term symptomatic products rather than primary disease-modifying therapy.
• Others include dyspepsia, acid indigestion, gastritis-related discomfort, epigastric burning, post-meal fullness and related upper-GI symptoms. This segment is characterized by considerable overlap between consumer-perceived acidity and clinically distinct gastrointestinal conditions. NIDDK notes that indigestion can have several causes and may require different treatments, including H2 blockers, PPIs or therapy directed toward H. pylori.

Antacids Market By Distribution Channel • Retail pharmacies remain a fundamental distribution channel because they combine product availability with pharmacist guidance. This is particularly important when consumers must choose between an immediate-relief antacid and an acid-suppressing product such as an H2 blocker or PPI. Pharmacy environments also support recommendations concerning drug interactions, dosing and when persistent symptoms warrant medical evaluation.
• Hospital pharmacies serve a more clinically supervised segment. Their importance is greater for patients with diagnosed GERD, peptic ulcer disease, gastritis, reflux complications and other gastrointestinal disorders. Purchasing decisions in this channel are more strongly influenced by physician treatment plans, hospital formularies and medication-management protocols than by spontaneous consumer purchases.
• Online pharmacies / E-commerce have expanded the convenience of gastrointestinal self-care by allowing consumers to compare formulations, brands, pack sizes and prices before purchasing. The channel is particularly suitable for repeat purchases of familiar products and can support multi-pack and subscription-style purchasing. Detailed online product information can also help consumers compare active ingredients and dosage forms.

Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Antacids Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Acid Neutralizers
• Proton Pump Inhibitors (PPIs)
• H2 Antagonists
• Pro-Motility Agents
• Combination Formulations

By Dosage Form
• Tablets & Chewables
• Liquid Suspensions
• Powders
• Gels & Syrups
• Gummies & Other

By Indication
• Gastroesophageal Reflux Disease
• Heartburn
• Peptic Ulcer
• Others

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies / E-Commerce